Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences develops bioelectric medicine technology based on its proprietary nPulse platform, which uses nanosecond pulsed field ablation energy to deliver nanosecond electrical pulses for non-thermal cell clearing. Company news commonly centers on the nPulse Cardiac Catheter System for atrial fibrillation, clinical study disclosures, feasibility data, and presentations at electrophysiology and healthcare conferences.
Recurring updates also cover the company's work in selected applications such as surgical soft tissue ablation, investor presentations and analyst events, executive leadership changes, operating and financial results, governance matters, and capital-structure disclosures related to its common stock and financing programs.
Pulse Biosciences (PLSE), a pioneer in Nanosecond Pulsed Field Ablation™ (nano-PFA) technology, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management team is scheduled to deliver their presentation on Wednesday, January 15, 2025, at 3:45 PM Pacific Time.
Investors and interested parties can access both the live and recorded versions of the presentation through the company's investor relations website, specifically on the 'Events Calendar and Presentations' page at investors.pulsebiosciences.com.
Pulse Biosciences (PLSE) has announced plans to redeem its first tranche of common stock warrants ('150% Warrants') from its July 2024 rights offering. The redemption notice will be delivered around December 27, 2024, with a redemption date of February 5, 2025. Warrant holders can exercise their rights at $11.00 per share until the redemption date. Any unexercised warrants will be redeemed for $0.01 per warrant share.
The company's right to redeem these warrants was triggered as its volume weighted average price exceeded $16.50 for twenty consecutive trading days, averaging $18.85. The company received $60 million from its initial Rights Offering and could receive an additional $66 million if all warrants are exercised. The second tranche (200% Warrants) is not being redeemed at this time.
Pulse Biosciences (Nasdaq: PLSE), a bioelectric medicine company, announced on December 18, 2024, that its Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants acquired in the company's 2024 rights offering. This transaction, valued at $58.4 million, resulted in the acquisition of 5,306,156 shares of common stock. Additionally, Mr. Duggan purchased another 156,714 shares of Pulse Biosciences between December 11 and December 13, 2024. These actions have increased Mr. Duggan's ownership in the company to approximately 70%.
Pulse Biosciences (PLSE) announced the publication of preclinical study results in the Journal of Thoracic and Cardiovascular Surgery, demonstrating advantages of their nano-PFA Cardiac Surgical System over radiofrequency technology for cardiac tissue ablation. The study showed the system's ability to create consistent, transmural ablations in all four heart chambers within 1.25 seconds per application, without damaging adjacent organs.
The system, which received FDA Breakthrough Device Designation in July 2024, operates approximately twenty times faster than current thermal ablation technologies. The company is conducting a multi-center, first-in-human atrial fibrillation feasibility study in three Netherlands centers, with preliminary results expected in late 2025.
Pulse Biosciences (PLSE) announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation (nano-PFA) for treating benign thyroid nodules. The study, presented at the 2024 American Thyroid Association Annual Meeting, showed that nano-PFA treatment reduced nodule sizes by over 50% and provided symptomatic relief within the first month. The company's Percutaneous Electrode System demonstrated effectiveness without residual fibrosis or scarring. The 30-patient clinical trial (NCT06117085) is being conducted in Naples, Italy, with plans for a pivotal trial in mid-2025 to support U.S. commercialization.
Pulse Biosciences (PLSE) reported Q3 2024 financial results and business updates. The company placed nsPFA Percutaneous Electrode Systems at seven U.S. sites and treated 9 patients in their atrial fibrillation study. They also treated over 50 patients with their nano-PFA 360° Cardiac Catheter. Financial highlights include GAAP costs of $13.7M (up from $11.3M YoY), GAAP net loss of $12.7M (vs $10.6M YoY), and cash position of $79.0M as of September 30, 2024. The company raised $60M through a rights offering in July 2024, with potential for additional $66M through warrant exercises.
Pulse Biosciences (PLSE) has appointed Dr. David Kenigsberg as Chief Medical Officer of Electrophysiology and added Dr. Andrea Natale as a medical advisor. Dr. Kenigsberg, founder of Florida Heart Rhythm Specialists, joins to support the development of the company's nano-PFA 360 Cardiac Catheter. Dr. Natale, Executive Medical Director of Texas Cardiac Arrhythmia Institute, will join existing advisors Dr. Vivek Reddy and Dr. Jacob Koruth to advance the clinical development of the catheter technology for treating atrial fibrillation.
Pulse Biosciences (Nasdaq: PLSE), a company specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its plans to release third quarter 2024 financial results on Wednesday, October 30, 2024, after the market closes. The company will host a conference call at 1:30pm PT / 4:30pm ET on the same day to discuss the results.
Investors can participate in the call by dialing 1-877-407-0752 (domestic) or 1-201-389-0912 (international). Additionally, a live and recorded webcast of the event will be available on the company's investor relations website at http://investors.pulsebiosciences.com/.
Pulse Biosciences (Nasdaq: PLSE) reported business updates and preliminary Q2 2024 financial results. Key highlights include:
1. Completed first soft tissue ablation procedures in the US using the Percutaneous Electrode System.
2. Performed initial epicardial ablations for atrial fibrillation treatment in Europe.
3. Expanded enrollment for the endocardial ablation study.
4. Raised $60 million through a rights offering.
5. Q2 2024 financials: $11.7 million in GAAP costs and expenses, $9.4 million in non-GAAP costs and expenses, and $26.2 million in cash and equivalents as of June 30, 2024.
6. Granted inducement options to new employees totaling 215,000 shares.
Pulse Biosciences (Nasdaq: PLSE) has appointed Paul A. LaViolette to its Board of Directors as Co-Chairman alongside Robert W. Duggan. LaViolette brings 40 years of medical technology development, operating, and leadership expertise to the company, which specializes in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. His extensive experience includes roles as Chief Operating Officer at Boston Scientific and current positions as Managing Partner at SV Health Investors and director for Edwards Lifesciences. LaViolette's appointment is expected to provide valuable insights and expertise to help Pulse Biosciences develop transformational treatments and maximize the potential of its proprietary technology across various therapeutic categories.